Vesole, David H.

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 933

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 861

Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood

Immunotherapy and Immune ResponsesMultiple Myeloma Research and Treatments

Cited by 388

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Stadtmauer, E. A., Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 259

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D., & Jagannath, S. (2008) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 126

Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

Hari, P. N., Zhang, M.-J., Roy, V, Pérez, W. S., Bashey, A., To, L. B., Elfenbein, G., Freytes, C. O., Gale, R. P., Gibson, J., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 100

Transplantation for multiple myeloma: who, when, how often?

Bladé, J., Vesole, D. H., & Gertz, M. A. (2003) · Blood

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 88

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

Gill, S. K., Unawane, R., Wang, S., Ahn, J., Aleman, A., Siegel, D. S., Vesole, D. H., Parmar, H., Phull, P., & Biran, N. (2022) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16